Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2022 Earnings Conference Call May 12, 2022 4:00 PM ET

Company Participants

Sasha Damouni Ellis - VP, Corporate Communications, and IR

Scott Braunstein - Chief Executive Officer

Joe Hulihan - Chief Medical Officer

Steve Pfanstiel - Chief Financial Officer

Mark Paternoster - Medicines Development Leader

Christy Shafer - Chief Commercial Officer

Conference Call Participants

Marc Goodman - SVB

Joseph Thome - Cowen

Andrew Tsai - Jefferies

Douglas Tsao - H.C. Wainwright

Brian Skorney - Baird

Joon Lee - Truist Securities

Jay Olson - Oppenheimer

Operator

Greetings, and welcome to the Marinus Pharmaceuticals First Quarter 2022 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]

And now it is my pleasure to introduce your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations. You may begin.

Sasha Damouni Ellis

Thank you, and good afternoon, everyone. With me from Marinus are Dr. Scott Braunstein, Chief Executive Officer; Dr. Joe Hulihan, Chief Medical Officer; and Steve Pfanstiel, Chief Financial Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the company's reports filed with the Securities and Exchange Commission, including Form 10-K, 10-Q and 8-K.

I will now turn the call over to our CEO, Scott Braunstein.

Scott Braunstein

Thank you, Sasha, and welcome to our call. This has been an exceptional year for the company, marked by the FDA's approval of ZTALMY for the treatment of seizures associated with CDKL5 deficiency disorder. We have been diligently preparing to bring our first product to market and are on track to launch the ZTALMY commercially in the U.S. in July, which Steve will speak to in greater detail.

It has also been a busy year on other fronts, specifically advancing our pipeline. We were pleased to announce earlier this month that our Phase III double-blind placebo-controlled trial in status epilepticus, the RAISE trial, reinitiated screening and recruitment. Our teams have been working diligently behind the scenes to ensure that sites would be ready to begin screening immediately after we ship new clinical supplies. I could not be more proud of the efforts by the entire Marinus team and the cooperation and dedication of our clinical sites.